Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PDE5i Use in Renal Transplant Recipients
NCT04122105 · University of British Columbia · NA · withdrawn · last registry update 2024-05-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “iss” | – | Registry record, University of British Columbia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-06Results posted on the registry: Mezzion Pharma Co. Ltd, Udenafil (NCT02201342)
- 2025-02-21Results posted on the registry: Rutgers, The State University of New Jersey, Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (NCT04410328)
- 2025-02-04Also stopped (terminated): Actelion, Inhaled Iloprost (5 μg) + Inhaled Placebo (NCT00302211)
- 2025-02-03Phase 3 first posted: Sanofi, Tadalafil 5 mg tablets with a digital tool. (NCT06805513)
- 2025-01-30Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tadalafil + Pembrolizumab (NCT05014776)
- 2025-01-29Phase 3 first posted: The University of Texas Medical Branch, Galveston, Sildenafil (NCT06800092)
- 2024-12-06Also stopped (withdrawn): Universidad del Norte, Sildenafil Injectable Product (NCT04912726)
- 2024-12-05Phase 3 first posted: Regina Elena Cancer Institute, PDE5 inhibitor (tadalafil) (NCT06717711)
- 2024-11-27Phase 3 first posted: Beni-Suef University, • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf (NCT06707181)
- 2024-11-27Results posted on the registry: University of California, Los Angeles, Ibudilast + Placebo oral capsule (NCT03594435)
- 2024-10-30Results posted on the registry: MediciNova, Ibudilast + Placebo (NCT04429555)
- 2024-10-15Results posted on the registry: University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-15Also stopped (terminated): University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-01Results posted on the registry: Philips Clinical & Medical Affairs Global, a drug against PDE5A (NCT04696354)
- 2024-09-25Also stopped (terminated): Iain Bressendorff, ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (NCT05897372)
- 2024-09-24Results posted on the registry: MediciNova, ibudilast + Ibudilast (NCT02714036)
- 2024-09-23Results posted on the registry: Boston Medical Group, a drug against PDE5A (NCT03596047)
- 2024-09-04Phase 3 first posted: Aswan University Hospital, Botulinum toxin A + Tadalafil 5mg (NCT06583590)
- 2024-08-02Results posted on the registry: Shionogi, MT-1186 + Rosuvastatin (NCT04481789)
- 2024-07-26Phase 3 first posted: University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06522854)
- 2024-07-25Phase 3 first posted: University Medical Centre Ljubljana, Tadalafil 5mg (NCT06520839)
- 2024-07-10Results posted on the registry: Montefiore Medical Center, Sildenafil + Placebo Oral Tablet (NCT03199612)
- 2024-07-08Phase 3 first posted: Tanta University, Vardenafil 5 Mg Oral Tablet (NCT06491108)
- 2024-06-20Phase 3 first posted: Al-Azhar University, Tadalafil (NCT06466369)
- 2024-05-20Phase 3 first posted: Ain Shams University, Dapagliflozin 10mg Tab + Pentoxifylline 400 MG (NCT06421870)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision